Feb 26 (Reuters) - Novavax raised its adjusted revenue forecast for 2026 on Thursday, banking on milestone payments from ...
Pfizer has signed a deal worth up to $530m with US-based vaccine technology company Novavax. This agreement will see Pfizer hand over $30m upfront for the non-exclusive rights to Novavax’s proprietary ...
Novavax (NVAX) is back in focus after Q4 2025 results showed surprise profitability, with revenue of US$147.14 million and net income of US$17.53 million, supported by key vaccine partnerships and ...
Q4 2025 Earnings Call February 26, 2026 8:30 AM ESTCompany ParticipantsLuis Sanay - Vice President of Investor RelationsJohn Jacobs ...
Hosted on MSN
COVID-19 vaccines: Get the facts
Find out about the different types of coronavirus disease 2019 (COVID-19) vaccines, how they work, the possible side effects, and the benefits for you and your family. Getting a COVID-19 vaccine helps ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results